Strides Pharma Science · NSE: STAR · BSE: 532531

Q1 FY26 results · Apr–Jun 2025

Strides Pharma Science reported revenue from operations of ₹1,119.74 crore (up 3.0% from Q1 FY25) and net profit of ₹105.59 crore (up 54.6% from Q1 FY25) for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.

Consolidated · ₹ crore
Item	Q1 FY26	Q1 FY25	YoY	Q4 FY25	QoQ
Revenue from operations	1,119.74	1,087.51	+3.0%	1,190.39	−5.9%
Other income	8.58	12.72	−32.5%	11.98	−28.3%
Total income	1,128.32	1,100.22	+2.6%	1,202.37	−6.2%
Profit before share of associates & JVs and tax	121.94	96.98	+25.7%	103.25	+18.1%
Share of profit/(loss) of associates & JVs	0.10	(11.80)		3.13
Net profit for the period	105.59	68.31	+54.6%	85.62	+23.3%
Attributable to shareholders of the company	99.61	70.20	+41.9%	82.19	+21.2%
EPS, basic (₹)	10.81	7.64	+41.5%	8.92	+21.2%
Net margin (%)	9.4	6.3		7.2

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q1 FY26	Q1 FY25	YoY	Q4 FY25	QoQ
Revenue from operations	498.62	554.75	−10.1%	555.96	−10.3%
Other income	1.76	11.83	−85.1%	12.12	−85.5%
Total income	500.37	566.58	−11.7%	568.08	−11.9%
Profit before tax	16.40	5.66	+189.6%	28.32	−42.1%
Net profit for the period	13.35	3.92	+240.6%	16.13	−17.2%
EPS, basic (₹)	1.45	0.43	+237.2%	1.75	−17.1%
Net margin (%)	2.7	0.7		2.9

Consolidated

Filed with BSE: 29 Jul 2025, 14:54 IST
Board meeting: 29 Jul 2025
Period: 01 Apr 2025 to 30 Jun 2025
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 29 Jul 2025, 14:54 IST
Board meeting: 29 Jul 2025
Period: 01 Apr 2025 to 30 Jun 2025
Review status: Unaudited
Source: XBRL filing on BSE